Skip to main content

Advertisement

ADVERTISEMENT

News

News
10/29/2024
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE...
10/29/2024
Oncology
News
10/29/2024
According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.
According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.
According to updated 5-year...
10/29/2024
Oncology
News
09/18/2024
Based on results from the KEYNOTE-483 study, the US FDA has approved pembrolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Based on results from the KEYNOTE-483 study, the US FDA has approved pembrolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Based on results from the...
09/18/2024
Oncology

Advertisement

Nicolas Girard, MD
Videos
09/14/2024
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
Nicolas Girard, MD, PhD,...
09/14/2024
Oncology
Conference Coverage
09/09/2024
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically...
09/09/2024
Oncology
Conference Coverage
09/09/2024
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically...
09/09/2024
Oncology

Advertisement

News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
10/16/2023
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
09/23/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology

Advertisement

News
07/20/2023
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology

Advertisement